We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.

AusPAR: Dolutegravir (as sodium)

Australian Public Assessment Report

AusPAR

AusPAR: Dolutegravir (as sodium) [PDF, 1.95 MB]

AusPAR: Dolutegravir (as sodium) [Word, 2.94 MB]

Attachment: Product Information: Dolutegravir (as sodium) [PDF, 354.01 KB]

Attachment: Product Information: Dolutegravir (as sodium) [Word, 122.68 KB]

Attachment: Extract from Clinical Evaluation Report: Dolutegravir (as sodium) [PDF, 2.31 MB]

Attachment: Extract from Clinical Evaluation Report: Dolutegravir (as sodium) [Word, 3.79 MB]

Device/Product Name

Tivicay

Active ingredients

Dolutegravir (as sodium)

AusPAR Date

19 May 2014

Published

20 June 2014

Submission Number

PM-2012-04124-1-2

Submission Type

New chemical entity

Decision

Approved